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Summary
CDC now has an expanded access investigational new drug (IND) protocol in effect with the 
Food and Drug Administration (FDA) to make miltefosine available directly from CDC to 
clinicians for treatment offree-living ameba (FLA) infections in the United States.
Background
Infections caused by FLA are severe and life-threatening. These infections include primary 
amebic meningoencephalitis (PAM) caused by Naegleriafowleri* and granulomatous amebic 
encephalitis caused by Balamuthia mandrillarisf and Acanthamoeba species.§ Although several 
drugs have in vitro activity against FLA, mortality from these infections remains greater than 
90% despite treatment with combinations of drugs.
Miltefosine is a drug used to treat leishmaniasis and also has shown in vitro activity against FLA
(1), but as an investigational drug, it has not been readily available in the United States. With 
CDC assistance, however, miltefosine has been administered in combination with other drugs 
since 2009 for FLA infections as single-patient emergency use with permission from the Food 
and Drug Administration. Although the number of B. mandrillaris and Acanthamoeba species 
infections treated with a miltefosine-containing regimen is small, it appears that a miltefosine- 
containing treatment regimen does offer a survival advantage for these usually fatal infections
(2). Miltefosine has not been used successfully to treat a Naegleria infection, but the length of 
time it has taken to import miltefosine from abroad has made timely treatment of fulminant 
Naegleria infections with miltefosine difficult.
CDC now has an expanded access IND protocol in effect with the Food and Drug Administration 
to make miltefosine available directly from CDC for treatment of FLA in the United States. The 
expanded access IND use of miltefosine for treatment of FLA is partly supported by 26 case 
reports of FLA infection from around the world during the period of 2008-2012 in which 
miltefosine was part of the treatment regimen (Unpublished data, Division of Foodborne, 
Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious 
Diseases, CDC, 2013). Miltefosine is generally well-tolerated, with gastrointestinal symptoms as 
the most commonly reported adverse effects.
Recommendations
Clinicians who suspect they have a patient with FLA infection who could benefit from treatment 
with miltefosine should contact CDC to consult with an FLA expert. See the For More 
Information section below for information on contacting a CDC FLA expert.
For More Information
• For diagnostic assistance, specimen collection guidance, specimen shipping instructions, 
treatment recommendations, and information on obtaining miltefosine from CDC, clinicians 
should contact the CDC Emergency Operations Center at 770-488-7100 to request to speak 
to an FLA expert.
• For more information on diagnostic assistance specimen collection guidance and specimen 
shipping instructions, see http://www.cdc.gov/parasites/naegleria/diagnosis-hcp.html.
• For Naegleria fowleri treatment recommendations, see 
http://www.cdc.gov/parasites/naegleria/treatment-hcp.html.
• For the MMWR Notice to Readers on this topic, see 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6233a4.htm7s cid=mm6233a4 w.
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• Additional information available at http://www.cdc.gov/parasites/naegleria.
f Additional information available at http://www.cdc. gov/parasites/balamuthia.
§ Additional information available at http://www.cdc.gov/parasites/acanthamoeba.
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by 
preventing and controlling diseases and injuries; enhances health decisions by providing 
credible information on critical health issues; and promotes healthy living through strong 
partnerships with local, national and international organizations.
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